



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To,

Date: 14.02.2022

BSE Limited
P.J. Towers, Dalal Street,
Mumbai-400 001

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 14.02.2022

Ref: Company's letter dated 28.01.2022

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Monday, 14.02.2022 at 5:00 PM at the registered office of the Company at Survey No.249, Brahmanapally Village, Hayatnagar Mandal-501511, the following were considered and approved:

1. Unaudited financial results for the quarter ended 31.12.2021. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LODR) Regulations, 2015 for the quarter ended 31.12.2021. **(Enclosed)**

The meeting concluded at 5.30 p.m.

This is for the information and records of the Exchange, please.

Thanking you.


Yours sincerely,
For Concord Drugs Limited

S. Nagi Reddy

S. Nagi Reddy
Chairman & Managing Director
DIN: 01764665



Encl: As above



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31st December 2021

[Rs. in Lakhs]

Particulars	Quarterly ended			Nine months ended		Year ended
	31-Dec-21 (UnAudited)	30-Sep-21 (unAudited)	31-Dec-20 (UnAudited)	31-Dec-21 (UnAudited)	31-Dec-20 (UnAudited)	31-Mar-21 (Audited)
I Revenue from Operations						
a. Net sales from Operations	1,344.167	983.08	824.073	4,349.191	4,301.071	5,135.70
b. Other Operating Income	2.767	2.80	0.666	7.719	7.31	9.46
II Other Income						
III Total Revenue (I+II)	1,346.934	985.88	824.74	4,356.910	4,308.38	5,145.16
IV Expenses						
a. Cost of Material Consumed	1,065.862	743.09	614.422	3,375.439	3,496.372	4,049.15
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	15.746	-72.21	2.659	37.985	126.107	168.67
c. Employees Benefit Expenses	120.295	103.82	95.166	328.995	283.257	375.55
d. Finance Costs	18.309	30.55	21.736	144.620	114.541	142.03
e. Depreciation and Amortisation expense	29.512	56.67	38.745	139.350	103.517	136.53
f. Other expenses	39.393	44.53	46.675	189.217	145.994	220.35
Total Expenses	1,289.117	906.45	819.40	4,139.636	4,269.79	5,092.28
Profit/ (Loss) before Exceptional item and tax (III-IV)	57.817	79.43	5.34	217.274	38.59	52.88
V Exceptional Items	-	-	352.3	-	352.34	376.32
VI Profit/ (Loss) before tax (V-VI)	57.817	79.43	357.67	217.274	390.92	429.20
VII Tax Expense:	15.676	33.63	87.8	60.569	96.48	101.03
VIII a. Current tax	9.559	27.74	39.770	61.981	46.91	47.07
b. Deferred tax charge/credit	6.117	5.89	48.062	1.412	49.56	53.96
IX Profit/ (Loss) for the period (VII-VIII)	42.141	45.79	269.84	156.705	294.45	328.17
X Other Comprehensive Income						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	42.141	45.79	269.841	156.705	269.84	328.17
XI Paid-up equity share capital (Face value of the share- Rs. 10 each)	874.375	874.38	874.38	874.375	874.38	874.38
Other Equity	1,958.95	1,916.81	1,743.92	1,958.95	1,743.92	1,802.25
XII Earnings per share (of Rs. 10 each)						
XIII a. Basic (in Rs)	0.482	0.52	3.09	1.792	3.09	3.75
b. Diluted (in Rs)	0.482	0.52	3.09	1.79	3.09	3.75

Notes:

1	The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
2	The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14th february ,2022
3	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
4	The results are also available on the website of the Company www.concorddrugs.in

Place: Hyderabad
Date: 14th February, 2022

By Order of the Board
For Concord Drugs Limited

Managing Director
DIN: 01764665





PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

D.No. 3-6-666, 3rd Floor, Barwale Chambers, Street No.11, Himayat Nagar,
Hyderabad - 500 029, Cell : 9440464339, Ph : 040 - 40072693,

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.

Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 31 December 2021, and the year to date results for the period 1 April 2021 to 31 December 2021, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Pundarikashyam and Associates
Chartered Accountants**

FRN: 011330S

B. Surya Prakasa Rao

B. Surya Prakasa Rao

(Partner)

MNo: 205125

Udin:

Place: Hyderabad

Date: 14-02-2022

UDIN: 22205125ACCQK08171.

